Alliances
The license and collaboration agreement allows Janssen to use F-star’s proprietary technology in the research, development and commercialization of novel bispecific antibodies.
Genomics veteran Bob Ragusa is taking over GRAIL, a newly-acquired business unit of Illumina, Inc. He is taking over as CEO Hans Bishop steps down from his role.
On October 6, 2021, Bristol Myers Squib and Celgene terminated the original deal related to Abraxane and gave BeiGene 180 days of notice that it was withdrawing Abraxane from the deal.
Four leading pharmaceutical companies partnered with Amazon Web Services and Israel Biotech Fund to launch AION Labs, an innovation space that will allow drug developers to harness AI and computational science to solve therapeutic challenges.
Merck and Acceleron struck an $11.5 billion merger agreement, but before that, rare-disease focused Acceleron Pharma was wooed by multiple suitors, including pharma giant Bristol Myers Squibb.
Seattle-based Immusoft announced it had inked a research pact and license option deal with Takeda to create, develop, and market cell therapies in rare inherited metabolic diseases with CNS manifestations and complications.
Genome-editing company Intellia Therapeutics and France-based SparingVision have partnered to develop new therapies for ocular diseases. The deal could be worth up to $600 million for Intellia.
Takeda entered into a licensing pact with Poseida, Spark entered into a licensing agreement with CombiGene AB, while BridgeBio Pharma announced plans for its second annual R&D Day.
Mirati and Sanofi will assess the combination of adagrasib and SAR442720 in a Phase I/II study in patients with previously treated non-small-cell lung cancer who express KRASG12C mutations.
Patients and patient organizations, which have detailed insights in the natural history of a rare disease, should be integral, too.
PRESS RELEASES